5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 3.34▼ | 3.32▼ | 3.27▲ | 3.17▲ | 3.24▲ |
MA10 | 3.25▲ | 3.26▲ | 3.26▲ | 3.13▲ | 3.30▲ |
MA20 | 3.36▼ | 3.39▼ | 3.40▼ | 3.26▲ | 3.25▲ |
MA50 | 3.48▼ | 3.38▼ | 3.39▼ | 3.38▼ | 2.72▲ |
MA100 | 3.48▼ | 3.38▼ | 3.32▼ | 3.19▲ | 3.20▲ |
MA200 | 3.15▲ | 3.01▲ | 2.96▲ | 2.79▲ | 5.38▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.011▲ | 0.002▲ | -0.005▼ | 0.017▲ | -0.036▼ |
RSI | 46.861▼ | 47.333▼ | 47.818▼ | 53.637▲ | 55.154▲ |
STOCH | 66.642 | 61.427 | 57.657 | 23.256 | 31.066 |
WILL %R | -39.024 | -39.024 | -47.368 | -44.505 | -58.748 |
CCI | 4.988 | -2.157 | -7.791 | 70.163 | -9.121 |
Monday, July 07, 2025 01:10 PM
July 7, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the ...
|
Monday, July 07, 2025 01:01 PM
July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of ...
|
Tuesday, June 24, 2025 12:56 PM
Inventiva S.A. (NASDAQ:IVA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva S.A. (NASDAQ ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
09/07/25 | 3.31 | 3.46 | 3.13 | 3.3744 | 19,184 |
08/07/25 | 3.1999 | 3.6907 | 3.1999 | 3.46 | 79,111 |
07/07/25 | 3.01 | 3.20 | 3.01 | 3.02 | 11,900 |
03/07/25 | 3.1013 | 3.1013 | 3.01 | 3.01 | 7,112 |
02/07/25 | 3.05 | 3.2262 | 2.98 | 2.98 | 7,137 |
01/07/25 | 3.07 | 3.09 | 2.98 | 2.98 | 2,931 |
30/06/25 | 3.09 | 3.40 | 3.00 | 3.19 | 12,969 |
27/06/25 | 3.0516 | 3.2032 | 3.03 | 3.05 | 7,534 |
26/06/25 | 3.17 | 3.2916 | 3.013 | 3.1654 | 13,230 |
25/06/25 | 3.19 | 3.19 | 3.00 | 3.07 | 30,714 |
|
|
||||
|
|
||||
|
|